ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
11 hedge funds and large institutions have $5.7M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
22% more funds holding
Funds holding: 9 → 11 (+2)
17% more capital invested
Capital invested by funds: $4.89M → $5.7M (+$812K)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
4.68% less ownership
Funds ownership: 20.15% → 15.46% (-4.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$585K |
| 2 |
SG
StoneX Group
New York
|
+$269K |
| 3 |
BL
BCWM LLC
Overland Park,
Kansas
|
+$264K |
| 4 |
RPG
Risk Paradigm Group
Austin,
Texas
|
+$15.8K |
| 5 |
BBPWM
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
|
+$9.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$51.8K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$35.1K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
-$17K |
| 4 |
Morgan Stanley
New York
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BL
1
BCWM LLC
Overland Park,
Kansas
| $3.73M | +$264K | +11,665 | +8% |
|
|
2
Jane Street
New York
| $595K | +$585K | +25,846 | New |
|
|
3
Royal Bank of Canada
Toronto,
Ontario, Canada
| $540K | -$35.1K | -1,550 | -6% |
|
|
4
LPL Financial
San Diego,
California
| $477K | -$51.8K | -2,292 | -10% |
|
|
SG
5
StoneX Group
New York
| $274K | +$269K | +11,889 | New |
|
|
BBPWM
6
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $28K | +$9.05K | +400 | +50% |
|
|
GT
7
Glenmede Trust
Philadelphia,
Pennsylvania
| $17K | – | – | – |
|
|
RPG
8
Risk Paradigm Group
Austin,
Texas
| $16.1K | +$15.8K | +700 | New |
|
|
AG
9
Advisor Group
Phoenix,
Arizona
| $14K | – | – | – |
|
10
Fifth Third Bancorp
Cincinnati,
Ohio
| $2K | +$2.26K | +100 | New |
|
|
LTFS
11
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
|
12
Creative Planning
Overland Park,
Kansas
| – | -$17K | -689 | Closed |
|
|
13
Morgan Stanley
New York
| – | -$2K | -100 | Closed |
|
CNCR Hedge Fund Activity: Q2 2017 in Review
11 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q2 2017, worth a combined $5.7M — up 17% from $4.89M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CNCR positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $585K. The largest seller was LPL Financial, cutting an estimated $51.8K.
- 11 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q2 2017, up from 9 in Q1 2017.
- Funds reported $5.7M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q2 2017, up 17% quarter-over-quarter.
- 4 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q2 2017 and 2 closed out, a net change of +2 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q2 2017 was Jane Street, an estimated $585K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q2 2017 was LPL Financial, an estimated $51.8K sold.
Based on aggregated 13F filings for Q2 2017.